Why CDMOs Need to Plan for Commercialization from Day One

For CDMOs, successfully manufacturing a product during clinical development doesn’t necessarily mean the same processes will work at commercial scale.

Early-stage manufacturing often prioritizes speed, flexibility, and getting products into clinical trials. But as products move toward commercialization, the requirements change. Production volumes increase, regulatory expectations evolve, and manufacturing operations become more complex.

And it’s not just about scaling existing products.

As CDMOs grow, they also need to accommodate new sponsors, different manufacturing processes, and customer requirements they may not have anticipated.

The challenge is building an operating model that can support today’s manufacturing needs without limiting tomorrow’s opportunities.

Commercial readiness shouldn’t begin when a product approaches commercialization. It should be part of how manufacturing operations are designed from Day One.

Clinical Success Doesn’t Guarantee Commercial Readiness

A manufacturing process that works well during clinical development may not be designed to support commercial production.

The challenge isn’t necessarily the process itself, but whether the operating model around it can scale.

What Works in Clinical Manufacturing May Not Scale

Clinical manufacturing often involves smaller batches, lower production frequency, and teams closely involved in managing each step.

As products move toward commercialization, higher production volumes, more frequent batches, and greater documentation and quality oversight requirements place additional demands on operations.

Processes that rely on manual coordination, individual expertise, or product-specific workarounds can become increasingly difficult to sustain.

The Cost of Planning Too Late

When commercial readiness becomes a priority only as a product approaches commercialization, CDMOs may need to redesign workflows, update manufacturing systems, and perform additional validation while preparing to increase production.

These changes can introduce delays, consume resources, and complicate an already demanding transition.

The goal isn’t to build a commercial operation during clinical development, but to avoid decisions that could constrain future growth.

Plan for More Than Increased Production Volumes

Commercialization isn’t simply about producing more batches. It introduces new manufacturing requirements, greater operational complexity, and expectations that extend beyond the original clinical program.

Commercial Growth Introduces New Requirements

As products progress toward commercialization, CDMOs may need to accommodate different batch sizes, equipment configurations, production schedules, quality processes, and reporting requirements.

What worked for a single product or manufacturing line may need to extend across additional facilities, teams, or production environments.

The challenge isn’t just increasing capacity. It’s maintaining consistent execution as manufacturing requirements evolve.

Your Next Customer May Need Something Different

For CDMOs, commercial readiness also means preparing for customers they haven’t onboarded yet.

Every new sponsor brings unique products, processes, manufacturing requirements, and expectations. An operating model designed too narrowly around existing programs can make onboarding new customers more time-consuming and resource-intensive.

CDMOs need a foundation that accommodates those differences without redesigning processes and systems for every new program.

The goal is to prepare not only for more manufacturing, but for different manufacturing.

Build Capabilities, Not Just Solutions for Today’s Needs

CDMOs often make technology and operational decisions around immediate manufacturing needs. But a solution designed for one product or sponsor may become a limitation when the next program introduces different requirements.

The Difference Between a Feature and a Capability

A feature addresses a specific requirement. A capability allows an organization to address similar requirements repeatedly, even as products, processes, and customer expectations change.

For example:

• Instead of building unique workflows for every product, establish configurable manufacturing processes that accommodate different requirements.
• Instead of recreating documentation for each new program, develop reusable templates, recipes, and standardized processes.
• Instead of relying on individual expertise, capture manufacturing knowledge within systems that support consistent execution across teams and sites.

Design for Requirements You Haven’t Encountered Yet

No CDMO can predict every future product, sponsor, or manufacturing requirement.

But organizations can build operational foundations that allow them to adapt without constantly redesigning existing processes or introducing new workarounds.

The strongest CDMOs aren’t trying to predict every future requirement. They’re building the capabilities to respond when those requirements emerge.

Make Commercial Readiness Part of Early Manufacturing Decisions

Commercial readiness isn’t achieved through a single investment or process change. It’s influenced by decisions made throughout clinical development, long before commercial production begins.

Think Beyond the Immediate Program

Early decisions around process design, equipment integration, manufacturing documentation, data capture, and quality workflows can determine how easily a product transitions to commercial manufacturing.

For example, designing a manufacturing process with configurable parameters and reusable templates can make it easier to accommodate changes in batch size, equipment, or production requirements without rebuilding the entire workflow.

The objective isn’t to overengineer clinical manufacturing. It’s to avoid making short-term decisions that create unnecessary limitations later.

Build with Commercialization in Mind

By considering future production requirements early, CDMOs can establish processes, systems, and manufacturing knowledge that support a smoother transition to commercial operations.

This doesn’t eliminate the need for process changes or additional validation as products advance. But it can reduce unnecessary rework and help organizations respond more efficiently when those changes become necessary.

Commercial Readiness Is Also About Sponsor Confidence

Commercial readiness can also influence how sponsors evaluate manufacturing partners. They want confidence that a CDMO can support their product as manufacturing requirements evolve.

Sponsors Are Evaluating More Than Manufacturing Capacity

Manufacturing capacity and technical expertise are important, but they don’t tell the whole story.

Sponsors also need assurance that a CDMO can maintain consistent execution, manage quality and compliance, provide reliable manufacturing data, and adapt as their product moves through development and potentially into commercial production.

The ability to support future requirements can be just as important as meeting today’s manufacturing needs.

Demonstrate the Ability to Grow with the Program

CDMOs that build scalable processes and adaptable manufacturing capabilities are better positioned to demonstrate long-term readiness to prospective sponsors.

Rather than simply promising additional capacity, they can show how their operating model supports changing production volumes, new requirements, and consistent execution as programs evolve.

Commercial readiness isn’t just about preparing for future production. It’s about giving sponsors confidence that you’re prepared to grow with them.

How MES Supports Commercial Readiness from Day One

A Manufacturing Execution System (MES) provides the digital foundation to support evolving products, customers, and production requirements without rebuilding execution processes for every new program.

Establish a Scalable Manufacturing Foundation

A pharma-focused MES enables CDMOs to standardize core manufacturing processes while accommodating different products and sponsor requirements.

Configurable recipes, reusable templates, electronic batch records, and integrated manufacturing data help establish consistent execution across products, production lines, and sites.

This reduces the effort required to onboard new programs while supporting quality, compliance, and operational consistency.

Build for Tomorrow Without Overcomplicating Today

Commercial readiness doesn’t mean implementing every capability immediately. It means establishing a foundation that can accommodate future requirements.

POMSnet Aquila is a pharma-first MES designed to support evolving manufacturing needs, from clinical development through commercial production.

The goal isn’t simply to scale production. It’s to build the capabilities to support whatever comes next.

Prepare Your Manufacturing Operations for What’s Next

This article is part of our series exploring how leading CDMOs are managing manufacturing complexity, improving execution, and preparing for future growth. Explore the full perspective in Scaling Pharma Manufacturing: What Leading CDMOs Are Doing Differently.

POMS can help you evaluate how your manufacturing systems can support future commercial growth.

Ready to build for commercialization from Day One? Talk to POMS.